Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -44.41% is 52% above its 5-year average of -92.23%, near the high end of its 5-year range (-321.28%–-32.98%).
21.06% above its 12-month average of -56.25%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.02%.
RETURN ON ASSETS (ROA)
-44.41%
RETURN ON ASSETS (ROA) AVG TTM
-56.25%
RETURN ON ASSETS (ROA) AVG 3Y
-49.77%
RETURN ON ASSETS (ROA) AVG 5Y
-92.23%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+21.06%
CURRENT VS 3Y AVG
+10.78%
CURRENT VS 5Y AVG
+51.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.76%
median of 426 covered companies
CURRENT VS SECTOR MEDIAN
-86.95%
vs the sector median at left
AN2 Therapeutics, Inc.
Market Cap
$202.05M
Return on Assets (ROA)
-44.41%
TTM Avg
-56.25%
3Y Avg
-49.77%
5Y Avg
-92.23%
Market Cap
$206.61M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$192.97M
Return on Assets (ROA)
-78.16%
TTM Avg
-23.70%
3Y Avg
-68.26%
5Y Avg
-50.80%
Market Cap
$218.42M
Return on Assets (ROA)
25.43%
TTM Avg
5.08%
3Y Avg
-10.27%
5Y Avg
-14.74%
Market Cap
$184.12M
Return on Assets (ROA)
-6.21%
TTM Avg
-15.18%
3Y Avg
-15.88%
5Y Avg
-16.43%
Market Cap
$220.94M
Return on Assets (ROA)
-58.10%
TTM Avg
-37.08%
3Y Avg
-28.02%
5Y Avg
-25.91%
Market Cap
$179.70M
Return on Assets (ROA)
-17.38%
TTM Avg
-167.34%
3Y Avg
-136.62%
5Y Avg
-286.91%
Market Cap
$176.96M
Return on Assets (ROA)
-534.43%
TTM Avg
-94.69%
3Y Avg
-82.47%
5Y Avg
-71.30%
Market Cap
$174.17M
Return on Assets (ROA)
-41.88%
TTM Avg
-12.18%
3Y Avg
-27.40%
5Y Avg
-32.78%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $202.05M | -44.41% | -56.25% | -49.77% | -92.23% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -78.16% | -23.70% | -68.26% | -50.80% |
| Compugen Ltd. (CGEN)vs › | $218.42M | 25.43% | 5.08% | -10.27% | -14.74% |
| Journey Medical Corporation (DERM)vs › | $184.12M | -6.21% | -15.18% | -15.88% | -16.43% |
| Alector, Inc. (ALEC)vs › | $220.94M | -58.10% | -37.08% | -28.02% | -25.91% |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | -17.38% | -167.34% | -136.62% | -286.91% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -534.43% | -94.69% | -82.47% | -71.30% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -41.88% | -12.18% | -27.40% | -32.78% |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -68.50% | -29.78% | -39.51% | -30.76% |
ROA
-44.4%
ROE
-47.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -56.78% |
| 2024-12-31 | -55.73% |
| 2023-12-31 | -46.66% |
| 2022-12-31 | -39.93% |
| 2021-12-31 | -32.98% |
| 2020-12-31 | -321.28% |
| 2019-12-31 | -593.16% |
